MedTrace Logo

A Trial of HRS-1780 in Participants With Uncontrolled Hypertension or Resistant Hypertension.

NCT07708441 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 914

Last updated 2026-07-16

No results posted yet for this study

Summary

The study is being conducted to evaluate the efficacy and safety of HRS-1780 in participants with uncontrolled hypertension or resistant hypertension. To explore the optimal use of HRS-1780 in participants with uncontrolled hypertension or resistant hypertension。

Conditions

  • Uncontrolled or Resistant Hypertension

Interventions

DRUG

HRS-1780 tablet

HRS-1780 tablet Dose 1

DRUG

HRS-1780 tablet

HRS-1780 tablet Dose 2

DRUG

HRS-1780 tablet

HRS-1780 tablet Dose 3

DRUG

HRS-1780 tablet placebo

HRS-1780 tablet placebo

Sponsors & Collaborators

  • Shandong Suncadia Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2029-04-30
Completion
2029-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07708441 on ClinicalTrials.gov